← All trials
NCT04310592
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 12, 2020
- Primary completion
- Jan 3, 2022
- Completion date
- Jan 3, 2022
- First posted
- Mar 17, 2020
- Last posted
- Mar 17, 2020
- Enrollment
- 22
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Celularity, Inc.Lead sponsor
- Celularity, Inc.Study director
Drugs studied
Indications studied
- Alkylating Agents
- Analgesics
- Anti-Infective Agents
- Antimetabolites, Antineoplastic
- Antiviral Agents
- Hematologic Diseases
- Immunologic Factors
- Immunosuppressive Agents
- Leukemia
- Leukemia, Myeloid
- Neoplasms
- Neoplasms by Histologic Type
- Leukemia, Myeloid, Acute
- Peripheral Nervous System Agents
- Analgesics, Non-Narcotic
- Hematologic Neoplasms
- Physiological Effects of Drugs
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.